MML Investors Services’s Corcept Therapeutics CORT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.94M Buy
22,264
+9,592
+76% +$579K ﹤0.01% 1555
2026
Q1
$511K Sell
12,672
-519
-4% -$19.4K ﹤0.01% 2207
2025
Q4
$459K Buy
13,191
+2,560
+24% +$201K ﹤0.01% 2317
2025
Q3
$884K Buy
10,631
+1,351
+15% +$97.8K ﹤0.01% 1819
2025
Q2
$681K Buy
9,280
+2,519
+37% +$183K ﹤0.01% 1900
2025
Q1
$772K Buy
6,761
+1,676
+33% +$102K ﹤0.01% 1739
2024
Q4
$256K Sell
5,085
-1,770
-26% -$92.7K ﹤0.01% 2359
2024
Q3
$317K Buy
+6,855
New +$244K ﹤0.01% 2143
2024
Q2
Sell
-44,622
Closed -$1.12M 2495
2024
Q1
$1.12M Buy
+44,622
New +$1.05M ﹤0.01% 1353
2023
Q4
Sell
-20,479
Closed -$558K 2454
2023
Q3
$558K Buy
+20,479
New +$593K ﹤0.01% 1558
2019
Q2
Sell
-16,899
Closed -$198K 1605
2019
Q1
$198K Sell
16,899
-238
-1% -$2.96K ﹤0.01% 1499
2018
Q4
$229K Sell
17,137
-1,932
-10% -$25.5K ﹤0.01% 1302
2018
Q3
$267K Buy
+19,069
New +$266K ﹤0.01% 1330
2018
Q2
Sell
-13,174
Closed -$217K 1358
2018
Q1
$217K Buy
+13,174
New +$244K ﹤0.01% 1236

Other funds holding CORT

MML Investors Services's CORT Position: Q2 2026 in Review

MML Investors Services increased its Corcept Therapeutics (CORT) stake by 76% in Q2 2026, buying an estimated $579K and bringing the position to 22,264 shares worth $1.94M. The position accounts for ﹤0.01% of the portfolio, ranked #1555.

MML Investors Services first reported a position in CORT in Q1 2018 and has held it in 14 quarters since. 188 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • MML Investors Services held 22,264 shares of Corcept Therapeutics worth $1.94M as of Q2 2026.
  • MML Investors Services bought 9,592 Corcept Therapeutics shares in Q2 2026, an estimated $579K.
  • Corcept Therapeutics made up ﹤0.01% of MML Investors Services's portfolio in Q2 2026, its #1555 holding.
  • MML Investors Services first reported a position in Corcept Therapeutics in Q1 2018 and has held it in 14 quarters since.
  • 188 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on MML Investors Services's 13F filing for Q2 2026, filed 7 Aug 2026.